(1) To review available data supporting the efficacy, effectiveness and adverse effects of infliximab in the treatment of patients with Crohn's disease (CD).
(2) To review available data evaluating the economic impact of infliximab used to treat patients with CD.
(3) To conduct a primary cost-utility analysis of infliximab treatment for patients with active CD resistant to conventional therapy.